DECEMBER 2023RiverVest Venture Partners Promotes Karen Spilizewski and Isaac Zike to Managing Director and Pascal Krotee to Principal ST. LOUIS (December 14, 2023)ST. LOUIS, December 14, 2023 – RiverVest Venture Partners today announced the promotions of three current team members: Karen Spilizewski and Isaac Zike, Ph.D....
November 2023RiverVest's Pascal Krotee Wins Life Science Catalyst Award Pascal Krotee, Ph.D. RiverVest Senior Associate San Diego, CA (November 1, 2023) – Biocom California today announced the winners of its Eighth Annual Life Science Catalyst Award. RiverVest Senior Associate Pascal Krotee, Ph.D. was among 10 life science...
RiverVest's latest Expert Insight explores the role of patient advocacy groups in therapeutic drug development for patients with rare diseases such as mitochondrial disease. ...
This is a case study of RiverVest portfolio company Good Therapeutics, which was acquired by Roche in 2022 for $250 million upfront plus potential milestone returns....
In this article, Managing Director Niall O’Donnell, Ph.D. discusses the law that transformed orphan drug development and how one actor’s starring role in its passage spurred 40 years of prolific, life-saving innovation. ...
This is a case study of RiverVest's role in financing and guiding Cincinnati-based portfolio company Standard Bariatrics through acquisition by Teleflex, Inc....
JAN 2020RiverVest's Tom Melzer Forecasts St. Louis VC, Start-up Growth for 2020 /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} ST. LOUIS (January 3, 2020) St. Louis Business JournalRead the Press ReleasePerhaps no part of the St. Louis economy surged in the past decade more...